Bojmar's lab

He’s now surgical consultant and PhD investigating risk factors and outcomes of colorectal cancer in younger patients. His collaboration with the Bojmar Lab began in 2022.
#ColorectalCancer #SurgicalOncology #ClinicalResearch

🩺 Meet Erik Lundqvist

MD, Surgical Consultant, PhD.
A native of Söderköping, Erik studied medicine at Linköping. The overall aim with his research is to improve the diagnosis and management of patients with colorectal cancer, affecting almost 7000 new individuals in Sweden each year.

She joined the Bojmar group in 2022 and leads the collection and processing of patient materials—essential to projects on EV biomarkers and the pre‑metastatic niche. Outside of work, she enjoys kayaking, gardening and arts.
#ResearchEngineer #LabOperations #Biomaterials

🧬 Meet Carolin Jönsson

Research Engineer
Born in southern Germany, Carolin trained at the Max‑Planck Institute and later worked in Switzerland and Toronto before moving to Sweden in 1993.

After working in Reykjavik, she’s now back in Linköping, contributing to clinical data collection for upcoming projects in the Bojmar group.
#PancreasSurgery #ClinicalResearch #SurgicalOncology

🩺️ Meet Karin Johansen

MD, PhD
From Gothenburg, Karin graduated from Linköping’s medical school in 2018. Her PhD was in pancreatic surgery, cost‑effectiveness, and quality of life.

Under Linda Bojmar’s supervision, he’s investigating molecular markers that influence radiotherapy response in colorectal cancer, focusing on extracellular vesicle cargo and the establishment of pre‑metastatic niches.
#ColorectalCancer #PhDLife #EVresearch

🔬 Meet Jonas Burman

PhD candidate
Raised in Karlstad, Jonas moved to Linköping for his bachelor's in biology and later completed a master’s in Experimental & Medical Biosciences in 2022. He did an international exchange in the Lyden lab, at Weill Cornell Medicine in New York.

He emphasizes the power of large collaborative networks to address clinical challenges and integrates closely with the Bojmar Lab’s translational work.
#SurgicalOncology #TranslationalResearch #HPBsurgery

🩺 Meet Bergthor Björnsson

MD, PhD, Docent / Senior Consultant
Bergthor’s clinical and translational research centers on pancreatic and liver surgery—he has led randomized and multicenter trials at Linköping.

After earning her master’s in medicine at Linköping, she joined Linda Bojmar’s team in April 2023 to study cancer‑derived extracellular vesicles—their role in progression and potential as biomarkers.
#Oncology #EVResearch #PhDLife

🩺 Meet Elena Arlaman

MD, PhD candidate
Elena was born and raised from Syria and studied pharmacy at Damascus University before relocating to Sweden in 2014, and completing MD training at Linköping University. She's currently an oncology resident and researcher.

His passion for pancreatic cancer began in clinical work, and now continues his research at the Department of Clinical Pathology, Linköping University Hospital. Off‑lab, he loves hiking and climbing.
#PancreaticCancer #Pathology

🧫 🩺 Meet Håkon Andersen Blomstrand

Pathologist, MD PhD
Originally from Uppsala, Håkon earned his medical degree at Gothenburg in 2013 and his PhD last year at Linköping's University.

She co‑led early studies on the hepatic pre‑metastatic niche in pancreatic cancer patients, now heading a translational research lab in Sweden working across disciplines. When not bridging hospital and lab, she enjoys being outdoors with family and horses.
#CancerResearch #EVBiomarkers #TeamLead

🧪 Meet Linda Bojmar
PhD, Assistant Professor, Docent
Linda trained in Linköping and completed her post‑doc at Weill Cornell, focusing on extracellular vesicles and cancer progression.

ERC Starting Grant to Linda Bojmar Linda Bojmar has been awarded just over SEK 16 million from the European Research Council, ERC. Her research aims to increase understanding of how pancreatic cancer spreads in the body and how treatme...

Cancer researcher Linda Bojmar at Linköping University has been awarded a Starting Grant from
@erc.europa.eu to study how pancreatic #cancer spreads — and how treatment can be tailored to each patient.

#AcademicSky 🧪

liu.se/en/news-item/erc-starting-grant-till-linda-bojmar

Huge congratulations to our PI Linda Bojmar for leading this dream project and to all the new grantees shaping the future of science!

Yesterday the @erc.europa.eu announced the 2025 Starting Grant winners. We’re beyond thrilled and grateful that our project SYST-E-MET: Systemic Effects on Metastasis – a look beyond the tumor was selected for funding!

Pancreatic Cancer Research Highlights from ASCO Annual Meeting The 2025 ASCO meeting featured pancreatic cancer research including a new treatment modality and a new treatment combination.

The 2025 ASCO meeting featured research on pancreatic cancer, including a new treatment modality and a novel treatment combination. bit.ly/43VHWOL #OncoSky

Targeting metastasis in paediatric bone sarcomas - Molecular Cancer Paediatric bone sarcomas (e.g. Ewing sarcoma, osteosarcoma) comprise significant biological and clinical heterogeneity. This extreme heterogeneity affects response to systemic therapy, facilitates inh...

This work is the result of a great international collaboration!
Huge thanks to Darrell Green and Emma Bull for bringing together such a strong multidisciplinary team. Check out our review on paediatric bone sarcomas #PaedsOnc #SarcomaResearch

molecular-cancer.biomedcentral.com/articles/10....

We are a part of the #FOSTER consortium (Fight OsteoSarcoma Through European Research). It proposes to connect multidisciplinary and patient/parent advocate expertise, at a Pan-European level to improve biological, translational and clinical research on #osteosarcoma to ultimately improve survival.

It was incredibly motivating to see the impact of collaborative, patient-centered science.
An honor to be part of LiU’s first year at #SCRM.
We’re already looking forward to continuing our research and sharing new findings at next year’s meeting!

We also had the chance to hear @juditarvelund.bsky.social, inspiring PI and collaborator from @liu.se, present her work on oncolytic virus-based #immunotherapy for lymphoma, highlighting the powerful role of dendritic cells. (Check her profile to read more about her work!)

From our lab, Linda presented a talk on the hepatic #preMetastatic niche in #pancreaticcancer and how systemic effects of cancer may serve as biomarkers for metastasis.
Meanwhile, Mohamed, @jonasburman.bsky.social, and Verena contributed with poster presentations showcasing their exciting work!

This year was the 7th Swedish Cancer Research Meeting #SCRM and for the first time @liu.se @liucancer.bsky.social took part in the national programme committee. A big thanks to Lund University Cancer Centre @lunduniversity.bsky.social for hosting this year’s gathering! This is our lab's insight:

Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer - Nature Medicine A multi-modal analysis of pre-metastatic liver biopsies from patients with localized pancreatic cancer with a minimum of 3 years of follow-up shows that immunological, proliferative and metabolomic fe...

6/Timing of pancreas cancer metastasis. By profiling patient samples, the authors reveal immune remodeling in the pre-metastatic liver and propose liver sampling to determine pancreas cancer metastatic propensity.

David Lyden Weill Cornell

www.nature.com/articles/s41...

Bojmar Lab Cancer is a systemic disease. Our research focuses on understanding crosstalk between different organs in the human body, and how this affects cancer progression. We focus mainly on gastrointestinal c...

Curious about our research?🧬
Meet the Bojmar Lab and explore what drives our science!
Dive in here: liu.se/en/research/...

#CancerResearch #Metastasis #EVs #BojmarLab #TeamScience

Congratulations Mohamed!!!
hakanssonsstiftelse.se/forskning-oc...

Unlike normal cells, cancer cells can't convert homocysteine due to low MTR enzyme activity. We will investigate whether this methionine dependency is also present in patient tissue. If confirmed, adjusting homocysteine levels could help slow tumor growth without harming normal cells.